Enovis (NYSE:ENOV) Director Sharon Wienbar Purchases 924 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar bought 924 shares of Enovis stock in a transaction on Monday, November 9th. The shares were bought at an average price of $26.98 per share, for a total transaction of $24,929.52. Following the acquisition, the director owned 43,777 shares of the company’s stock, valued at approximately $1,181,103.46. The trade was a 2.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Enovis Stock Performance

Shares of ENOV stock opened at $28.25 on Wednesday. The stock has a market cap of $1.63 billion, a PE ratio of 8.44 and a beta of 1.31. The stock has a 50-day moving average of $20.05 and a 200-day moving average of $23.14. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08. Enovis Corporation has a one year low of $16.70 and a one year high of $32.41.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The business had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. During the same quarter last year, the firm earned $0.75 EPS. Enovis’s quarterly revenue was up 1.8% compared to the same quarter last year. As a group, sell-side analysts expect that Enovis Corporation will post 3.15 earnings per share for the current year.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. Paradigm Capital Management Inc. NY bought a new position in Enovis in the 2nd quarter valued at approximately $28,533,000. Bank of America Corp DE acquired a new position in Enovis in the second quarter valued at $11,502,000. Private Management Group Inc. lifted its holdings in Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after buying an additional 427,347 shares during the period. Man Group plc bought a new stake in Enovis during the second quarter valued at $8,711,000. Finally, Front Street Capital Management Inc. boosted its position in Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after acquiring an additional 384,124 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

ENOV has been the subject of several research analyst reports. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Canaccord Genuity Group reduced their price objective on shares of Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, November 6th. BTIG Research boosted their price objective on shares of Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Needham & Company LLC lifted their target price on shares of Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.62.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.